A Randomized Phase Ill Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Breast Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1)The tumor must be unilateral invasive adenocarcinoma of the breast. 2)The tumor must have been determined to be HER2-negative. 3)The patient must have undergone either a mastectomy or lumpectomy.

You may not be eligible for this study if the following are true:

  • 1) Patients who have T4 tumors including inflammatory breast cancer. 2) Patients who have definitive clinical or radiologic evidence of metastatic disease. 3) Patients who have synchronous or previous contralateral invasive breast cancer and previous history of ipsilateral invasive breast cancer or ipsilateral DCIS.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.